July 10 (Reuters) – Gilead Sciences Inc said on Friday additional data from a late-stage study showed its antiviral remdesivir significantly improved clinical recovery in severely ill COVID-19 patients.
Findings from an analysis of its late-stage study showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company said.
Gilead shares were up nearly 2% at $76.14 before the bell. (Reporting by Ankur Banerjee in Bengaluru; editing by Uttaresh.V)
